D
Doris A. Chernik
Researcher at Hoffmann-La Roche
Publications - 11
Citations - 1782
Doris A. Chernik is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Flurazepam & Midazolam. The author has an hindex of 7, co-authored 11 publications receiving 1681 citations.
Papers
More filters
Journal ArticleDOI
Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam.
Doris A. Chernik,Dennis Gillings,Harriet Laine,Judith Hendler,Jonathan M. Silver,Arnold B. Davidson,Elias M. Schwam,Judith L. Siegel +7 more
TL;DR: The Observer's Assessment of Alertness/Sedation (OAA/S) Scale was developed to measure the level of alertness in subjects who are sedated and was reliable and valid as measured by high correlation between the two raters and high correlations between the OAA/s Scale and two of the three standard tests used in this study.
Journal ArticleDOI
Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.
Christopher G. Goetz,Glenn T. Stebbins,H. M. Shale,Anthony E. Lang,Doris A. Chernik,Teresa A. Chmura,J. E. Ahlskog,Ernest Dorflinger +7 more
TL;DR: Physicians and coordinators found the Obeso dyskinesia scale easy to use and especially practical for rating dysKinesia severity and for identifying the most disabling dys kinesia.
Journal ArticleDOI
Sleep of Depressed Patients in Remission
TL;DR: Findings indicate that, in many patients, sleep is still disturbed more than six months after substantial clinical recovery from depression, and less homogeneity among formerly depressed patients than is found among controls.
Journal ArticleDOI
Efficacy Without Tolerance or Rebound Insomnia for Midazolam and Temazepam After Use for One to Three Months
TL;DR: The results of this study suggest that patients with chronic insomnia may benefit from 30 to 90 days of treatment, and a three‐factor model that separates pharmacologic from behavioral and psychologic effects of hypnotics was proposed to explain these results.
Journal ArticleDOI
Validity and reliability of the Neurobehavioral Assessment Scale.
Doris A. Chernik,Myron Tucker,Beth Gigli,Kisook Yoo,Kala Paul,Harriet Laine,Judith L. Siegel +6 more
TL;DR: The Neurobehavioral Assessment Scale (NAS) was developed to measure the full range of behavioral functioning from fully alert to deep coma and appears to be better able to discriminate among the different degrees of sedation in lightly sedated patients than the Glasgow Coma Scale.